Intertek expands one of Europe's largest GMP pharmaceutical stability storage facilities to meet growing customer demand
11 May 2026
Cambridge, UK: Intertek, a Total Quality Assurance provider for industries worldwide, has announced the expansion of its UK GMP (Good Manufacturing Practice) pharmaceutical stability storage facility in Royston near Cambridge, UK. With a total capacity of 625,000 litres, the expansion consolidates its position as one of the largest contract storage facilities in Europe.
Originally launched in 2015, this expanded facility enables Intertek to offer a wider range of bespoke storage conditions, alongside all typical International Conference on Harmonisation (ICH) temperature and relative humidity (RH) conditions, to meet the expanding needs of a global pharmaceutical client base.
The rapid growth of innovative drug development programmes in recent years has significantly increased demand for stability storage, integrated with expert GMP analytical services. The stability and integrity of sensitive components are key to the delivery of complex formulations such as biologic drug products. As a result, developers are increasingly looking for a wide range of storage facilities, from ultra-low-temperature storage of cell-based materials (-80°C and -150°C) to suitable storage of critical components of next-generation drug-device combination products for liquid inhalation, such as single-dose plastic nebules for nebuliser platforms.
Olivier Coppey, President, Global Pharmaceutical Services at Intertek, said: "This expansion cements our Royston facility as one of Europe's largest and most advanced GMP pharmaceutical stability storage sites. Combined with our teams' outstanding expertise in analytical and formulation support, we help our clients mitigate risk and keep their challenging pharmaceutical development programmes on track."
Teresa Iley, Director of Pharmaceutical Development and Manufacture at Intertek, added: "By offering pioneering standard and bespoke stability storage programmes, fully integrated with expert formulation development and specialised analytical capabilities such as GMP-compliant combination drug product testing, our customers gain deeper product insight and stronger regulatory readiness. We continuously expand our GMP expertise to ensure precise characterisation of purity, potency, identity and stability, supporting faster development of next-generation drug–device combination therapies.”
GMP stability testing is a key part of Intertek's pharmaceutical development services. In addition to Cambridge, UK, the company’s global ICH stability storage and testing locations include Manchester (UK), Whitehouse (New Jersey, USA), and Melbourne (Australia). Intertek has a 30-year heritage providing cGMP contract analytical, bioanalytical, stability and formulation support.
Learn more:
FOR MEDIA INFORMATION:
Please contact:
Lorna Kettle
Marketing Director, Intertek Pharmaceutical Services
T: +44 (0) 116 296 1620
E: lorna.kettle@intertek.com
About Intertek
Intertek is a leading Total Quality Assurance provider to industries worldwide.
Our network of more than 1,000 laboratories and offices in more than 100 countries, delivers innovative and bespoke Assurance, Testing, Inspection and Certification solutions for our customers' operations and supply chains. Intertek is a purpose-led company that brings Quality, Safety and Sustainability to Life.
Our Science-based Customer Excellence USP and the 24/7 mission critical Quality Assurance solutions we provide, ensure that our clients can operate with well-functioning supply chains in each of their operations.
Our Customer Promise is: Intertek Total Quality Assurance expertise, delivered consistently, with precision, pace and passion, enabling our customers to power ahead safely.
About Intertek Pharmaceutical Services
Intertek’s pharmaceutical services locations include Melbourn, Cambridge (UK), Manchester (UK), Basel (Switzerland), Whitehouse, (New Jersey, USA), Mumbai (India) and Melbourne, (Australia).
Intertek’s scientists continue to lead the way in pharmaceutical testing with this increased capacity for innovative drug development support. By partnering with us, pharmaceutical companies can ensure compliance, mitigate risks, and maintain the highest standards of product quality and safety.